The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.

Topics


  • Evaluation of drug-delivery strategies (including nanoparticles, liposomes and other delivery vehicles) and gene therapy approaches involving non-immunologic targets for the treatment of cancer.
  • Translational studies of novel antineoplastic agents and pre-clinical drug toxicity, pharmacokinetic/pharmacodynamic and biomarker studies of anticancer agents.
  • Development of anti-angiogenic therapeutic strategies and rational combinations of cytotoxic drugs with novel agents including those targeting: growth factors, signaling, cell cycle regulation, angiogenic, and differentiation pathways.
  • Development and application of mathematical and computational methods for the investigation of combination chemotherapy using small molecules and other modalities.
  • Therapeutic approaches involving biologic response modifiers either alone or in combination with novel or conventional drugs for cancer treatment.
  • Early-stage, pilot clinical trials of novel anticancer therapeutic and drug-delivery strategies involving pharmacokinetic, pharmacodynamic, toxicologic, or pharmacogenomic endpoints.

Shared Interests and Overlaps

There are shared interests with Nanotechnology (NANO) and Bioengineering, Technology, and Surgical Sciences (BTSS) in the areas of nanotechnology related to gene and drug delivery and nanodevices. Applications which focus on the design, synthesis, and development of nanostructures, nanodevices, and nanosystems that could serve as a platform technology for various biological/biomedical applications are appropriate for NANO. Applications which focus on these areas in the context of cancer therapy, are typically assigned to DT while those focused on the surgical setting are typically assigned to BTSS.

There are shared interests with Modeling and Analysis of Biological Systems (MABS) in the areas of mathematical and computer modelling. Applications which focus on the early development of the modeling are appropriate for MABS. Applications which seek to apply the modeling for investigation of combination chemotherapy using small molecules and other modalities for cancer therapy are typically assigned to DT.

There are shared interests with Gene and Drug Delivery Systems (GDD) in the areas of drug and gene delivery devices and vehicles as well as electroporation. Applications which focus on the early development and delivery of drugs, genes, and gene products that could serve as a platform technology for various biological/biomedical applications are appropriate for GDD. Applications that are further in development and focused on cancer therapy are typically assigned to DT.

There are shared interests with Cancer Immunopathology and Immunotherapy (CII) in the areas of oncolytic virotherapy and chemoimmunotherapy. Applications which focus on the immunological aspects are appropriate for CII. Applications more focused on the non-immunological aspects are typically assigned to DT.

There are shared interests with Radiation Therapeutics and Biology (RTB) in the areas of chemo and radiation therapy. Applications which focus on the radiotherapy aspects are appropriate for RTB while applications more focused on the chemotherapy aspects and utilize standard radiation therapy protocols are typically assigned to DT.

There are shared interests with Drug Discovery and Molecular Pharmacology (DMP) in the area of drug development. Applications focused on drug discovery and early drug development are appropriate for DMP while applications involving further development of lead compounds, etc. are typically assigned to DT.

There are shared interests with Clinical Oncology (CONC) in the area of clinical trials. Applications which focus more on the clinical trial and its correlative studies are appropriate for CONC while applications involving both pre-clinical and early phase clinical trials are typically assigned to DT.

There are shared interests with Mechanisms of Cancer Therapeutics-2 (MCT2) in the therapeutic evaluation of the anti-cancer drug effect. Applications that focus on the development of anti-angiogenic therapeutic strategies and rational combinations of cytotoxic drugs with novel agents may be assigned to DT. Applications that focus on identification, validation, and functional evaluation of novel molecular targets (including companion biomarkers) for cancer treatment and synergistic drug combination may be assigned to MCT2.

There are shared interests with Mechanisms of Cancer Therapeutics-1 (MCT1) on therapeutic strategies involving combinations of cytotoxic drugs with targeting agents. Studies with advanced animal experiments and pilot clinical trials may be assigned to DT. Applications focused on mechanism of action of combination therapies and the effects of drug combination on anabolic and catabolic processes may be assigned to MCT1.

There are shared interests with Clinical Neuroimmunology and Brain Tumors (CNBT) . Therapeutic studies of novel antineoplastic agents and pre-clinical drug toxicity for central nervous system tumors (glioma, medulloblastoma, etc.) may be assigned to DT. Applications involving central nervous system disorders where the focus is on immune response, inflammation and infections should be assigned to CNBT. ​